News | April 02, 2025
Emcutix and WiQo sign licensing partnership for derma-cosmetic treatments in India
PRX-PLUS has a unique product feature with its deep-impacting formula
PRX-PLUS has a unique product feature with its deep-impacting formula
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
The freshly infused capital will primarily be deployed towards expansion and research & development
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
Subscribe To Our Newsletter & Stay Updated
